La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Sernova Gestione

Gestione criteri di controllo 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Cynthia Pussinen

Amministratore delegato

CA$2.6m

Compenso totale

Percentuale dello stipendio del CEO	3.6%
Mandato del CEO	1.1yrs
Proprietà del CEO	n/a
Durata media del management	1.1yrs
Durata media del Consiglio di amministrazione	5.8yrs

Aggiornamenti recenti sulla gestione

Recent updates

Here's Why We're Not At All Concerned With Sernova's (CVE:SVA) Cash Burn Situation

Feb 23

We Think Sernova (CVE:SVA) Can Easily Afford To Drive Business Growth

Aug 11

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Cynthia Pussinen rispetto agli utili di Sernova?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jul 31 2024	n/a	n/a	-CA$39m
Apr 30 2024	n/a	n/a	-CA$41m
Jan 31 2024	n/a	n/a	-CA$41m
Oct 31 2023	CA$3m	CA$92k	-CA$39m

Compensazione vs Mercato: La retribuzione totale di Cynthia ($USD 1.89M ) è superiore alla media delle aziende di dimensioni simili nel mercato Canadian ($USD 176.00K ).

Compensazione vs guadagni: Dati insufficienti per confrontare la retribuzione di Cynthia con le performance aziendali.

AMMINISTRATORE DELEGATO

Cynthia Pussinen

1.1yrs

Mandato

CA$2,574,600

Compensazione

Ms. Cynthia Pussinen is Chief Executive Officer & Director at Sernova Corporation from September 2023. She served as an Executive Vice President of Technical Operations and Supply Chain at Actinium Pharmac...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Cynthia Pussinen	CEO & Director	1.1yrs	CA$2.57m	Nessun dato
James Parsons	CFO & Director	no data	CA$183.27k	0.12% CA$ 102.0k
Modestus Obochi	Chief Business Officer	1.1yrs	CA$996.01k	0.015% CA$ 13.3k
Frank Shannon	Vice President of Clinical Development & Regulatory Affairs	3.2yrs	CA$463.26k	Nessun dato
Jonathan M. Rigby	Executive Chairman	less than a year	Nessun dato	Nessun dato
Douglas Maret	Chief Science Officer	no data	Nessun dato	Nessun dato
Christopher Barnes	Vice President of Investor Relations	2.8yrs	CA$352.33k	Nessun dato
Marylyn Rigby	Chief Communications Officer	no data	Nessun dato	Nessun dato

1.1yrs

Durata media

Gestione esperta: Il team dirigenziale di SVA non è considerato esperto (durata media 0.9 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Cynthia Pussinen	CEO & Director	1.1yrs	CA$2.57m	Nessun dato
James Parsons	CFO & Director	12.5yrs	CA$183.27k	0.12% CA$ 102.0k
Jonathan M. Rigby	Executive Chairman	less than a year	Nessun dato	Nessun dato
Norman C. Wong	Member of Scientific Advisory Board	18.3yrs	Nessun dato	Nessun dato
Jannette Dufour	Member of Scientific Advisory Board	18.2yrs	Nessun dato	Nessun dato
George King	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Clive Patience	Member of Scientific Advisory Board	17.8yrs	Nessun dato	Nessun dato
Steven Paraskevas	Member of Scientific Advisory Board	13.8yrs	Nessun dato	Nessun dato
David Lillicrap	Member of Scientific Advisory Board	5.8yrs	Nessun dato	Nessun dato
Anke Schulte	Member of Global Advisory Board	4.3yrs	Nessun dato	Nessun dato
Stephen Sangha	Independent Director	1.5yrs	CA$158.36k	4.01% CA$ 3.5m
Sam Wiseman	Member of Scientific Advisory Board	3.5yrs	Nessun dato	Nessun dato

5.8yrs

Durata media

59yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di SVA sono considerati esperti (durata media dell'incarico 5.6 anni).

Sernova Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Sernova Corp. Appoints James Parsons as Chief Financial Officer

Independent Director recently sold CA$223k worth of stock

Less than half of directors are independent

Sernova Corp. Appoints Jonathan Rigby as Executive Chairman

Sernova Corp. Appoints Jonathan Rigby to Board of Directors

Sernova Corp., Annual General Meeting, Apr 30, 2024

Recent updates

Sernova Corp. Appoints James Parsons as Chief Financial Officer

Price target decreased by 18% to CA$2.88

Sernova Corp. Announces New Positive Data from Phase I/II Trial Regarding Islet Survival and Function

Sernova Corp. announced that it has received CAD 5.2 million in funding

Independent Director recently sold CA$223k worth of stock

Sernova Corp. announced that it expects to receive CAD 4 million in funding

Sernova Corp. announced that it expects to receive CAD 4 million in funding

Price target decreased by 14% to CA$3.52

Less than half of directors are independent

Sernova Corp. Appoints Jonathan Rigby as Executive Chairman

Sernova Corp. Appoints Jonathan Rigby to Board of Directors

New minor risk - Share price stability

New minor risk - Market cap size

Price target decreased by 13% to CA$3.53

Sernova Corp., Annual General Meeting, Apr 30, 2024

New minor risk - Financial position

Companies Like Sernova (TSE:SVA) Are In A Position To Invest In Growth

Sernova Corp. Announces New Advancements of Conformal Coating Technology in Combination with the Cell Pouch System™ at the 2023 IPITA-IXA-CTRMS Joint Congress

Sernova Announces Positive Ongoing Interim Phase 1/2 Clinical Data for the Cell Pouch System™ for Type 1 Diabetes Trial at the 2023 IPITA, IXA, and CTRMS Joint Congress

Sernova Corp. Announces New Preclinical Data for its Novel Cell Therapy Platform, Cell Pouch System, as Potential Treatment for Post-Operative Hypothyroidism at 2023 American Thyroid Association Annual Meeting

Price target decreased by 16% to CA$3.52

Sernova Corp. Provides Development Update on Proprietary Cellular Conformal Coating Technology in Combination with Cell Pouch Device

Sernova Corp. Appoints Cynthia Pussinen as Chief Executive Officer

We're Keeping An Eye On Sernova's (TSE:SVA) Cash Burn Rate

Chairman recently bought CA$238k worth of stock

Sernova Corp Appoints Modestus Obochi as Chief Business Officer

Sernova Corp. Announces Positive Updated Interim Phase 1/2 Clinical Data for the Cell Pouch System™? at American Diabetes Association 83rd Scientific Sessions

New major risk - Financial position

Sernova Corp. Announces Executive Changes

Less than half of directors are independent

We Think Sernova (TSE:SVA) Can Afford To Drive Business Growth

Sernova Corp., Annual General Meeting, Apr 27, 2023

Sernova Announces Advancements with Its Novel Cell Pouch System™ to Preserve Thyroid Function Following Total Thyroidectomy

Sernova Corp. Announces Executive Changes

Sernova Announces First Two Patients Implanted with Cell Pouch™ in the Second Cohort of Its US Phase 1/2 Clinical Trial for Type 1 Diabetes

Price target increased to CA$4.21

Sernova Receives Authorization to Enroll Second Patient Cohort of Phase 1/2 Trial with Cell Pouch System™ for Type 1 Diabetes

We Think Sernova (TSE:SVA) Can Afford To Drive Business Growth

Sernova Corp. Appoints Daniel Mahony, Ph.D. to Its Board of Directors, Effective from September 30, 2022

Executive Chairman of the Board recently bought CA$65k worth of stock

Sernova Corp. Announces Positive Updated Phase 1/2 Clinical Data on Cell Pouch System Tm at American Diabetes Association 82nd Scientific Sessions 2022

Sernova Corp.(TSXV:SVA) dropped from S&P/TSX Venture Composite Index

Sernova Corp. announced that it has received CAD 20.323499 million in funding from Evotec SE

Sernova Announces Abstract on Phase 1/2 Trial with Cell Pouch Selected for Oral Podium Presentation At American Diabetes Association 82Nd Scientific Sessions 2022

No longer forecast to breakeven

Here's Why We're Not At All Concerned With Sernova's (CVE:SVA) Cash Burn Situation

Sernova Corp., Annual General Meeting, Apr 28, 2022

Sernova Corp. Announces Publication of A Peer Reviewed Preclinical Study Demonstrating Positive Results of A Novel Cell Pouch System Cell Therapy

Sernova Corp. Provides Progress Update on Its Phase 1/2 T1d Clinical Trial

Sernova to Announce New Interim Results of its Type 1 Diabetes Clinical Trial During the 40th Annual J.P. Morgan Healthcare Conference

Sernova Announces Clinical Investigator Update of its Type 1 Diabetes Trial at the 2022 ASTS 22nd Annual Winter Symposium

Forecast to breakeven in 2024

We Think Sernova (CVE:SVA) Can Easily Afford To Drive Business Growth

Sernova's Principal Investigator Presents Positive New Data from Ongoing Type 1 Diabetes (T1D) Clinical Trial at ATC 2021 Virtual Connect Conference

Chief Financial Officer recently bought CA$78k worth of stock

Sernova Corp. has completed a Composite Units Offering in the amount of CAD 20.04 million.

Sernova Corp Announces Second Annual Data Safety Monitoring Board Review of its Diabetes Cell Pouch System Clinical Trial and Recommendation for Protocol Continuation

Independent Chairman exercised options to buy CA$272k worth of stock.

Sernova Corp. Announces Collaboration Agreements with Multiple Pharmaceutical Industry Leaders

New 90-day high: CA$0.75

New 90-day high: CA$0.57

New 90-day high: CA$0.31

Sernova Corp. Provides Clinical Update on U.S. Phase I/II Cell Pouch Trial for Type 1 Diabetes

New 90-day low: CA$0.26

Sernova Corp. announced that it has received CAD 3.6655 million in funding

Sernova Corp. announced that it expects to receive CAD 3 million in funding

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato